Novo Holdings is a holding and investment company that manages the assets and wealth of the Novo Nordisk Foundation, operating as a world-leading life sciences investor with over DKK 694 billion (EUR 93 billion) in total assets under management. It invests across all stages of development in biotechnology and medical technology companies, while also serving as the controlling shareholder of Novo Nordisk and Novonesis.
“It will pay up to $780 million for LimmaTech, a Swiss firm focused on bacterial pathogens like Staphylococcus aureus. It had raised $40m from firms like Tenmile, Repair Impact Fund, AXA Investment Managers, Novo Holdings, Adjuvant Capital and CARB-X.”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.